3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
5
Glioma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Glioblastoma
3
Rhabdoid Tumor
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Lymphoma
2
Liposarcoma
2
Fallopian Tube Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Sarcoma, Synovial
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Osteitis Deformans
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Interventions
Everolimus
5
Alpelisib
4
berzosertib
3
PX-866
3
Letrozole
3
Fulvestrant
3
Cetuximab
3
Topotecan
2
NVP-BKM120
2
tipifarnib
1
sotorasib
1
serabelisib
1
ribociclib
1
pembrolizumab
1
parsaclisib
1
palbociclib
1
gedatolisib
1
duvelisib
1
ceralasertib
1
capivasertib
1
binimetinib
1
Trimetazidine
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hereditary Sensory and Autonomic Neuropathies
×
ribociclib
×
Clear all
NCT03439046
2024-08-01
BioItaLEE
Novartis
Phase 3
Completed
287 enrolled